Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Dermata Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 8 | 6 | −2 |
| Shares | 143.5K | 104.8K | −38.7K (−27.0%) |
| Value | $236.3K | $110.1K | −$126.2K (−53.4%) |
New holders (2)
Institutions that held Dermata Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 12,237 | $13.0K | 0.00% |
| Two Sigma Securities, LLC | 11,087 | $11.8K | 0.00% |
Sold out (4)
Institutions that held Dermata Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Virtu Financial LLC | 32,105 | $53.0K |
| Citadel Advisors LLC | 17,190 | $28.5K |
| Susquehanna International Group, LLP | 12,563 | $20.9K |
| HCR Wealth Advisors | 12,000 | $19.8K |